Actively Recruiting
Liposomal Bupivacaine Versus Ropivacaine for Transversus Abdominis Plane Block in Laparoscopic Cholecystectomy: A Randomized, Single-Blind, Parallel-Group Trial
Led by Tianjin First Central Hospital · Updated on 2026-05-14
86
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the pain relief effectiveness of liposomal bupivacaine compared to ropivacaine when used for transversus abdominis plane (TAP) block in patients undergoing laparoscopic gallbladder removal surgery. This randomized, single-blind, parallel-group clinical trial focuses on improving postoperative pain management. The primary measure is the dynamic pain score 24 hours after surgery, with additional assessments of recovery quality, analgesic use, and complications over time. Participants will be randomly assigned to receive either liposomal bupivacaine or standard-dose ropivacaine administered via ultrasound-guided TAP block after surgery. Both groups will receive routine clinical care during their hospital stay. The study includes follow-up assessments up to three months after surgery to monitor the development of chronic post-surgical pain. During the study, participants will have their pain levels measured at 24, 48, and 72 hours after surgery, along with evaluations of recovery quality using the QoR-15 scale. Researchers will track the time until additional pain medication is needed, total pain medication used, gastrointestinal recovery, hospital stay length, and any adverse events. Follow-up visits will assess longer-term pain outcomes, with the entire study lasting up to three months after surgery.
CONDITIONS
Brief Title
Efficacy of Liposomal Bupivacaine for Transversus Abdominis Plane Block
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years, any gender
- Scheduled for elective laparoscopic cholecystectomy
- ASA physical status I to III
- Able to provide written informed consent and complete 3-month follow-up
You will not qualify if you...
- Allergy to local anesthetics
- History of dementia, psychosis, or other central nervous system diseases
- History of chronic pain or long-term opioid or analgesic use
- Contraindications to nerve block such as infection at puncture site or severe coagulopathy
- Severe liver or kidney dysfunction, pregnancy, or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Day of surgery
Participants undergo laparoscopic cholecystectomy followed by a transversus abdominis plane (TAP) block with either liposomal bupivacaine or ropivacaine.
1 visit (in-person)
Duration - Up to 7 days after surgery
Participants are monitored for pain, recovery quality, analgesic use, gastrointestinal function, and adverse events after surgery.
Visits at 24, 48, and 72 hours after surgery, and daily assessments through hospital discharge
Trial Site Locations
Total: 1 location
1
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China, 300384
Actively Recruiting
Research Team
K
Ke yu Zhang
L
Lili Jia
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here